# BPC-157 Side Effects: What the Research Literature Reports

> BPC-157 side effects as documented in preclinical literature and the three small human reports. Renal, cardiovascular, oncological, and drug-interaction data reviewed. No human safety studies exist.

## Human Safety Data: Current State of Evidence

Is BPC-157 safe for use in humans? No controlled trial has established this.

Three uncontrolled human reports have been published — knee injections, bladder injections, IV infusion. All three documented no adverse events. None were RCTs.

The 2025 narrative review concluded: robust preclinical evidence; three small human reports; no RCTs; BPC-157 should be treated as investigational [8].

Long-term safety in humans: unknown.

## BPC-157 and Renal Safety

Is BPC-157 hard on the kidneys? Published data do not document nephrotoxicity.

In the 2025 ischemia-reperfusion study (Demirtas et al.), BPC-157 reduced renal histopathological damage scores compared to the ischemia-reperfusion group. Glomerular vacuolization, tubular dilation, and hyaline casts were reduced. Antioxidant markers improved [17].

Human renal safety data: does not exist.

## BPC-157 and Cardiovascular Safety

Is BPC-157 bad for the heart? Direct cardiotoxicity has not been documented in published rodent studies.

The compound's angiogenesis-promoting mechanism (VEGFR2 upregulation) raises a theoretical concern: pathological angiogenesis. The 2025 Sikiric commentary argued the mechanism is modulatory — triggering angiogenesis at injury sites in response to tissue damage signals, not constitutively upregulating vascular growth factors.

No human cardiac safety data exists.

## BPC-157 Interactions

**NSAIDs:** BPC-157 demonstrated protective effects against diclofenac-, aspirin-, and indomethacin-induced GI and hepatic damage [9]. Protective interaction in rodent models.

**Alcohol:** BPC-157 demonstrated gastroprotective and hepatoprotective effects against alcohol-induced damage [10, 11, 20]. Protective in the preclinical model.

**Dopaminergic compounds:** BPC-157 modulated the effects of haloperidol (reduced catalepsy) and amphetamine (reduced hypermotility) in rodent models [16].

Human drug-drug interactions: unknown.

## The Oncological Question

Published preclinical studies have not documented tumor-promoting effects from BPC-157. The compound was not studied in tumor promotion models specifically.

The 2025 literature review (Jozwiak et al.) flagged the theoretical concern about VEGFR2 upregulation and angiogenesis, calling for caution in translating preclinical findings to human use [21].

In the absence of long-term human data, the oncological question cannot be answered.

## References

[8] McGuire FP, et al. Curr Rev Musculoskelet Med. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
[9] Ilic S, et al. Life Science. 2011;88(11-12). https://pubmed.ncbi.nlm.nih.gov/21295044/
[10] Sikiric P, et al. Life Science. 1993;53(18). https://pubmed.ncbi.nlm.nih.gov/7901724/
[11] Prkacin I, et al. J Physiol Paris. 2001;95(1-6). https://pubmed.ncbi.nlm.nih.gov/11595453/
[16] Vukojevic J, et al. Neural Regen Res. 2022;17(3). https://pubmed.ncbi.nlm.nih.gov/34380875/
[17] Demirtas H, et al. Medicina (Kaunas). 2025. https://pubmed.ncbi.nlm.nih.gov/40005408/
[20] Boban Blagaic A, et al. Eur J Pharmacol. 2004;499(3). https://pubmed.ncbi.nlm.nih.gov/15381050/
[21] Jozwiak et al. Pharmaceuticals. 2025. https://www.mdpi.com/1424-8247/18/2/185
[22] Xu X, et al. Front Pharmacol. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/

---

Neon-lit readouts from the peer-reviewed BPC-157 record — every stat logged, every citation indexed, no clinic behind the terminal.